Roche takes big step in weight-loss field with $5.3 billion deal. Novo Nordisk shares fall. - MarketWatch
1. Roche partners with Zealand Pharma for a $5.3 billion weight-loss drug deal. 2. Petrelintide, a weekly injection, targets better tolerability compared to existing drugs. 3. Zealand Pharma shares surged 29% in response to the deal announcement. 4. Analysts view Roche as a beneficial partner for Zealand Pharma's ambitions. 5. Potential drug launch timeframe estimated around 2029.